19 studies found for:    brca | Open Studies | United States, Massachusetts
Show Display Options
Rank Status Study
1 Recruiting Olaparib Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
Conditions: Newly Diagnosed;   Advanced Ovarian Cancer;   FIGO Stage III-IV;   BRCA Mutation;   Complete Response;   Partial Response;   First Line Platinum Chemotherapy
Intervention: Drug: Olaparib 300mg tablets
2 Recruiting Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa
Condition: Breast Cancer
Interventions: Drug: Cisplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin
3 Recruiting Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Conditions: Platinum Sensitive;   BRCA Mutated;   Relapsed Ovarian Cancer;   Following Complete or Partial Response to Platinum Based Chemotherapy
Interventions: Drug: Olaparib 300mg tablets;   Drug: Placebo to match olaparib 300mg
4 Recruiting The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: Veliparib;   Drug: Temozolomide;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Placebo
5 Recruiting Cisplatin vs Paclitaxel for Triple Neg BRCA
Condition: Triple Negative Breast Cancer
Interventions: Drug: Cisplatin;   Drug: Paclitaxel;   Procedure: Pre- and Post-chemotherapy clinical diagnostic tissue
6 Recruiting Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.
Condition: Breast Cancer Metastatic
Interventions: Drug: Olaparib;   Drug: Physician's choice chemotherapy
7 Recruiting S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Conditions: brca1 Mutation Carrier;   brca2 Mutation Carrier;   Breast Cancer
Interventions: Dietary Supplement: cholecalciferol;   Other: placebo
8 Recruiting Veliparib and Dinaciclib With or Without Carboplatin in Treating Patients With Advanced Solid Tumors
Conditions: BRCA1 Mutation Carrier;   BRCA2 Mutation Carrier;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: veliparib;   Drug: dinaciclib;   Drug: carboplatin;   Other: laboratory biomarker analysis;   Other: pharmacological study
9 Recruiting Standard Genetic Counseling With or Without a Decision Guide in Improving Communication Between Mothers Undergoing BRCA1/2 Testing and Their Minor-Age Children
Conditions: Breast Cancer;   Hereditary Breast/Ovarian Cancer (brca1, brca2)
Interventions: Other: counseling intervention;   Other: educational intervention;   Other: survey administration;   Behavioral: psychosocial assessment and care;   Behavioral: supportive care
10 Recruiting A Phase III Trial of Niraparib Versus Physician's Choice in Her2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Conditions: Carcinoma of Breast;   Human Epidermal Growth Factor 2 Negative Carcinoma of Breast;   BRCA1 Gene Mutation;   BRCA2 Gene Mutation
Interventions: Drug: niraparib;   Drug: Physician's choice
11 Recruiting Eribulin in HER2 Negative Metastatic BrCa
Condition: Breast Cancer
Intervention: Drug: Eribulin
12 Recruiting Palbociclib + Endocrine Therapy for HR + BrCa
Condition: Breast Cancer
Interventions: Drug: Palbociclib;   Drug: Endocrine Therapy
13 Recruiting A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
Condition: Breast Cancer
Intervention: Drug: PM01183
14 Recruiting HKI-272 for HER2-Positive Breast Cancer and Brain Metastases
Condition: Breast Cancer
Interventions: Drug: HKI-272;   Procedure: Surgical Resection;   Drug: Capecitabine
15 Recruiting Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa
Condition: Breast Cancer
Interventions: Drug: Trastuzumab;   Drug: Pertuzumab;   Drug: Paclitaxel;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Procedure: Mastectomy;   Radiation: Radiation Therapy
16 Recruiting A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
Intervention: Drug: Rucaparib
17 Recruiting The Cancer of the Pancreas Screening-5 CAPS5)Study
Conditions: Pancreas Cancer;   Peutz-Jeghers Syndrome;   Gene Mutation;   Germline Mutation Carrier;   Lynch Syndrome
Intervention: Drug: Human synthetic secretin
18 Recruiting A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer
Condition: Platinum Sensitive Ovarian Cancer
Interventions: Drug: Active comparator: Niraparib;   Drug: placebo
19 Recruiting Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca
Conditions: Recurrent Breast Cancer;   Metastatic Breast Cancer
Interventions: Drug: Ruxolitinib;   Drug: Paclitaxel

Indicates status has not been verified in more than two years